A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Active, not recruiting · Phase 1, Phase 2 · NCT02773030
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $1.5M
- U.S. investigators named
- 18
- Sites paid
- 18
- Planned or actual enrollment
- 466
About the trial
- Sponsor
- Celgene
- Tested
- CC-220 (drug), Dexamethasone (drug), Daratumumab (drug), Bortezomib (drug), Carfilzomib (drug), Daratumumab - 16mg/kg (drug), Bortezomib (BTZ) (drug), Daratumumab- 1800mg (drug)
- Dates
- Started 2016-10-14; completion 2028-07-28
- Results posted
- Yes
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.
From ClinicalTrials.gov, last updated 2026-03-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Celgene Corporation reported $1.5M in research payments for this study in 2025 (20 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Faiz Anwer, MD Hematology & Oncology · Tucson, AZ
- Peter L. Bergsagel, M.D. Hematology & Oncology · Scottsdale, AZ
- Sagar Lonial, M.D. Hematology · Atlanta, GA
- Paul G. Richardson, MD Hematology & Oncology · Boston, MA
- Ashraf Z. Badros, M.D. Medical Oncology · Baltimore, MD
- Matthew J. Pianko, M.D. Hematology · Ann Arbor, MI
- Jeffrey A. Zonder, MD Hematology & Oncology · Detroit, MI
- Manisha Bhutani, MD Hematology · Charlotte, NC
- Stefano Tarantolo, M.D. Hematology & Oncology · Omaha, NE
- Sundar Jagannath, M.D. Medical Oncology · New York, NY
- David Kaminetzky, M.D. Hematology & Oncology · New York, NY
- Brea C. Lipe, M.D. Hematology & Oncology · Rochester, NY
- Ruben Niesvizky, MD Hematology & Oncology · New York, NY
- Abdullah M. Khan, MBBS Hematology · Columbus, OH
- Al-ola A. Abdallah, M.D Internal Medicine · Tulsa, OK
- Brian L. Mcclune, DO Hematology & Oncology · Salt Lake City, UT
- Jorge M. Chaves, M.D. Hematology & Oncology · Tacoma, WA
- Andrew J. Cowan, M.D. Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $408,518
- Cleveland Clinic, OH $395,515
- Strong Memorial Hospital, NY $93,536
- Ohio State University Resear Fo $84,413
- Emory University Hospital, GA $82,355
- Mayo Clinic Hospital, AZ $71,990
- University of Michigan Health System, MI $63,579
- NYU Langone Hospitals - Tisch Hospitals Clinical Labs $47,963
- Northwest Medical Specialties, PLLC $45,814
- Mount Sinai School of Medicine $40,929
- Kumc Research Institute, Incorporated $37,247
- Weill Medical College of Cornell University $30,177
- University of Washington Medical Ctr, WA $24,608
- Oncology Hematology West P.c. Dba Nebraska Cancer Specialists $22,758
- Carolinas Medical Center-Northeast, NC $20,869
- Karmanos Cancer Center, MI $19,845
- University of Utah Hospital and Clinics, UT $15,908
- University of Maryland, Baltimore $9,815
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.